🎥@MarianaBrandao0 of @JulesBordet highlights the multifaceted considerations in defining operability for #NSCLC, shedding light on the challenges posed by stage III disease:

➡️⬅️

@BTOGORG #BTOG24 #LungCancer #LCSM

Assessing operability in NSCLC: challenges and considerations

Mariana Brandao, MD, PhD, Institute Jules Bordet, Brussels, Belgium, delves into the complexities of defining operabilit...

ow.ly

🫁Exciting insights from @CharlesSwanton at #BTOG24 on the link between air pollution and lung cancer initiation, shedding light on tumor formation mechanisms in never smokers:

➡️⬅️

@CR_UK @BTOGORG #LCSM #NSCLC

Lung cancer initiation: towards molecular cancer prevention

Charles Swanton, Francis Crick Institute in London, discusses his research on the initiation and progression of lung ...

ow.ly

🎥Natasha Leighl, MD, from @UofT shares insights from the CHRYSALIS trial at #AACR24, revealing promising responses to amivantamab in pts w/ #NSCLC, with notable exceptions in KRAS or HER2 mutations:

➡️⬅️

#LungCancer #CTSM #ImmunoOnc

CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC

Natasha Leighl, MD, University of Toronto, Toronto, Canada, discusses findings from the Phase Ib CHRYSALIS trial (NCT0...

ow.ly